CoChat
Sign Up
Cited by 48Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology ResearchDown syndrome and intellectual disability research

The DOI matches its Crossref record; 229 of the 229 references it cites were found in a registry or an index.

Molecular and Cellular Aspects of Mental Retardation in the Fragile X Syndrome: From Gene Mutation/s to Spine Dysmorphogenesis

De Rubeis, Silvia, Fernández, Esperanza, Buzzi, Andrea, Di Marino, Daniele, Bagni, Claudia·2012·Advances in Experimental Medicine and Biology
DOI 10.1007/978-3-7091-0932-8_23
Open this paper in CoChat — free account

Abstract

The Fragile X syndrome (FXS) is the most frequent form of inherited mental retardation and also considered a monogenic cause of Autism Spectrum Disorder. FXS symptoms include neurodevelopmental delay, anxiety, hyperactivity, and autistic-like behavior. The disease is due to mutations or loss of the Fragile X Mental Retardation Protein (FMRP), an RNA-binding protein abundant in the brain and gonads, the two organs mainly affected in FXS patients. FMRP has multiple functions in RNA metabolism, including mRNA decay, dendritic targeting of mRNAs, and protein synthesis. In neurons lacking FMRP, a wide array of mRNAs encoding proteins involved in synaptic structure and function are altered. As a result of this complex dysregulation, in the absence of FMRP, spine morphology and functioning is impaired. Consistently, model organisms for the study of the syndrome recapitulate the phenotype observed in FXS patients, such as dendritic spine anomalies and defects in learning. Here, we review the fundamentals of genetic and clinical aspects of FXS, devoting a specific attention to ASD comorbidity and FXS-related diseases. We also review the current knowledge on FMRP functions through structural, molecular, and cellular findings. Finally, we discuss the neuroanatomical, electrophysiological, and behavioral defects caused by FMRP loss, as well as the current treatments able to partially revert some of the FXS abnormalities.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-3-7091-0932-8_23

Cites

229 of 229 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Items 201–229 of 229

Cited by

Sorted by citations

See all 48

Related

See all

Metadata

Authors
De Rubeis, S., Fernández, E., Buzzi, A., Di Marino, D., & Bagni, C.
Affiliations
  • Vlaams Instituut voor Biotechnologie (BE)
  • University of Rome Tor Vergata (IT)
Corresponding author
Bagni, Claudia
ORCID
Venue
Advances in Experimental Medicine and Biology
Publisher
Springer Vienna
Published
2012
Volume
970
Pages
517-551
ISSN
0065-2598 (ISSN-L)
DOI
10.1007/978-3-7091-0932-8_23
OpenAlex
W2245762304
Cited by
48
References
229
Citations by year
2024: 2 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 4 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 7 · 2013: 15 · 2012: 8
FWCI
24.39
Type
book chapter
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Advances in experimental medicine and biology (publishedVersion)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
  • Lirias (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
Keywords
fragile X syndrome, FMRP, intellectual disability, autism spectrum disorder, RNA-binding proteins, mRNA degradation, synaptic dysfunction, learning deficits
MeSH terms
Animals, Brain, Child, Dendrites, Disease Models, Animal, Drosophila melanogaster, Fragile X Syndrome, Gonads, Humans, Male, Mutation, Phenotype, RNA, Messenger, Protein Biosynthesis, Zebrafish, Gene Expression, RNA Stability, Mice, Fragile X Messenger Ribonucleoprotein 1, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review